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Abstract
Background: Informed decision making is the theoretical basis in the UK for men's decisions
about Prostate Specific Antigen (PSA) testing for prostate cancer testing. The aim of this study is
to evaluate the effect of a web-based PSA decision-aid, Prosdex, on informed decision making in
men. The objective is to assess the effect of Prosdex on six specific outcomes: (i) knowledge of PSA
and prostate cancer-related issues – the principal outcome of the study; (ii) attitudes to testing; (iii)
decision conflict; (iv) anxiety; (v) intention to undergo PSA testing; (vi) uptake of PSA testing. In
addition, a mathematical simulation model of the effects of Prosdex will be developed.
Methods: A randomised controlled trial with four groups: two intervention groups, one viewing
Prosdex and the other receiving a paper version of the site; two control groups, the second
controlling for the potential Hawthorn effect of the questionnaire used with the first control group.
Men between the ages of 50 and 75, who have not previously had a PSA test, will be recruited from
General Practitioners (GPs) in Wales, UK. The principal outcome, knowledge, and four other
outcome measures – attitudes to testing, decision conflict, anxiety and intention to undergo testing
– will be measured with an online questionnaire, used by men in three of the study groups. Six
months later, PSA test uptake will be ascertained from GP records; the online questionnaire will
then be repeated. These outcomes, and particularly PSA test uptake, will be used to develop a
mathematical simulation model, specifically to consider the impact on health service resources.
Trial registration: Current Controlled Trial: ISRCTN48473735.
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Background
Prosdex is a web-based decision aid to help men consider
whether or not to have a Prostate Specific Antigen (PSA)
test, potentially for prostate cancer [1]. It was developed in
the context of the UK Prostate Cancer Risk Management
Programme (PCRMP), a strategy, promoted by the UK
National Cancer Screening Programme, which has, as one
of its key goals, the promotion of informed decision mak-
ing about PSA testing [2]. According to the strategy, men
should only have a PSA test if they have received appropri-
ate information and had the opportunity to make a deci-
sion – a decision which, for many, is difficult due to the
uncertainty of prostate cancer testing. Despite its increas-
ing incidence in men, the only widely-available test for
prostate cancer, PSA, is limited not only by its poor sensi-
tivity and specificity, but also by the uncertainty relating
to the natural history and the management of the disease
[2,3]. It is for these reasons that, unlike the USA, there is
not a PSA screening programme in the UK. Moreover, the
PCRMP strategy arguably reflects the tension between an
evidence-based approach to population testing – PSA in
this case – and the needs of individual men to make
informed decisions about their own health.
Decision aids have been developed for a range of health
conditions to facilitate informed decision making. Char-
acteristically, the risks and benefits of different options are
presented in a variety of formats and media, thereby help-
ing patients in the process of values clarification, seen as
fundamental for informed decision making. Prosdex was
developed in 2002–04, supported by a grant from Cancer
Research UK and the NHS Cancer Screening Programme
[1]. Hosted by Cardiff University, with links from NHS
Direct Online and Cancer Research UK, it presents evi-
dence-based information about prostate cancer and PSA
testing, encouraging users to weigh the pros and cons of
testing for themselves. In addition, Prosdex includes video
clips of enacted patient experiences about the PSA test and
subsequent investigations/treatments. There is also infor-
mation about 'shared decision making' and, through
structured decision support (the 'decision stacker'), Pros-
dex aims to actively encourage informed decision making.
The aim of this proposed study is to evaluate the effect of
Prosdex on informed decision making. In order to do so, a
range of outcome measures need to be considered, due to
the fact that a specific measure of informed decision mak-
ing in PSA testing has not been developed. Three of the
proposed outcome measures – knowledge, attitude to
testing, and test uptake – are constituents of an informed
decision making measure in another health context, pre-
natal Down syndrome [4]. These, and the other three pro-
posed outcome measures – decision conflict, anxiety and
intention to undergo testing – have been used in evalua-
tions, specifically randomised controlled trials, of other
PSA decision aids. In a systematic review of these trials, we
found that knowledge increased by 19.5% and PSA testing
decreased by 3.5% [5]. The six proposed outcome meas-
ures will, therefore, not only allow an assessment of the
effect of Prosdex on informed decision making, but also
will allow comparisons with other evaluations of PSA
decision aids. This will hopefully enable an appraisal of
implementation issues, for example the degree of aware-
ness of the complexity surrounding PSA testing engen-
dered in users by Prosdex[6]. Finally, a mathematical
simulation model, using data from the trial, will allow
extrapolations of the potential effects of Prosdex on health-
service resource use, for example the impact on urological
services, and on health outcomes.
Methods
i) Design
randomised controlled trial (RCT). This allows a compar-
ison of the effect of a single intervention (Prosdex) on the
specified outcomes in the objectives. The design employs
four randomised groups of men in order to distinguish
the effects of Prosdex from two other possible effects: for-
mat (electronic versus written), and the Hawthorne effect,
specifically the effect that participating in a clinical trial
could have on subsequent PSA uptake. RCTs have been
used successfully to evaluate the effects of other PSA deci-
sion aids in North America [7,8].
ii) Setting
Wales. Men recruited using GP lists.
iii) Participants
a) Inclusion criteria
Men between 50 and 75 will be invited to participate, as
prostate cancer is rare below the age of 50;[2] also, above
the age of 75, men would be less likely, in our opinion, to
complete the study, particularly the online questionnaire
element. The men will access the study via the internet
and must be able to use a computer. They will be asked to
indicate this on the consent form. The numbers unable to
participate due to this, in addition to those who fail to
respond to the invitation, will be counted separately, in
line with the CONSORT guidelines for reporting RCTs [9].
b) Exclusion criteria
Men who cannot read English will be excluded, as Prosdex
was developed first only in English. Also excluded will be
men who are known to have had prostate cancer and
those whose GP records indicate that they have had a PSA
test.
c) Recruitment process
Suitable men will be identified by GPs, in Wales, who will
also send the invitation letters, participant information
sheets (PIS) and consent forms. A member of the practiceBMC Family Practice 2007, 8:58 http://www.biomedcentral.com/1471-2296/8/58
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staff, probably the data manager, will be asked to identify
men, aged 50–75, who have not had a PSA test. Using that
generated list, the data manager will be asked to select 100
men using a serial recruitment process based on the date
of the month of the men's birthdays: that is, the first man
selected will be the first man on the list with a birthday
01/month/year; second man, 02/month/year; and so
forth up to 31 when the process will be repeated until 100
men are selected. A member of the practice staff who has
knowledge of the patients – Practice Manager or GP – will
then be asked to screen the list for men who, in their opin-
ion, are unsuitable for the trial due to serious ill-health.
The number of men thus removed will be reported.
Affirmative consent forms from each practice will be
transferred to the research officer who, in turn, will allo-
cate each participant from that practice with a number
provided the by trial statistician who will oversee the allo-
cation process. Accordingly, the participants will be ran-
domly allocated, by computer, to one of two intervention
groups or to one of two control groups. This process will
occur remotely in order to secure concealment. For each
practice, the statistician will allocate 80 numbers, gener-
ated in 'blocks', the number for which will be between 12
and 16 in order to guarantee 'balance'. Randomisation
will occur at the level of the man as we are interested in
individual decision-making outcomes, and there is
unlikely to be a significant intra-cluster correlation for
these outcomes [10]. There will be no randomisation of
the GP practices, but they will be stratified according to
socio-economic groups, with an aim of 4 different such
groups. After the collection of the data, there will be social
analysis of these groups.
iv) Intervention (see fig 1)
A specific version of the Prosdex website will be developed:
it will require a password for access and will generate the
online questionnaire. Men in intervention group 1 will be
asked to log onto and view the website, either in their own
homes or in another setting of their choice. The second
intervention group (2) will receive a paper document
comprising the text of the website. This enables evaluation
of the Prosdex features (e.g. video clips and the structured
decision support) that go beyond the mere presentation
of the text content. In the first control group (A), men,
after inserting their password, will be asked to complete
the online questionnaire without viewing Prosdex. The sec-
ond control group (B) will not initially be given the
details of the study website.
There are, therefore, two main comparisons:
1) Intervention Group 1 v Control Group A:
Prosdex (+ online questionnaire) against no intervention,
but with the online questionnaire: tests the effect of Pros-
dex content itself within the online context.
2) Intervention Group 1 v Intervention Group 2:
Two different formats to present almost identical content:
tests the effects of the media: online versus paper-based.
The comparison between Control Group A and Control
Group B allows a consideration of the Hawthorne effect of
the questionnaire on PSA testing, to aid interpretation of
outcomes in Intervention Groups 1 & 2.
At the six month stage, after the ascertainment of PSA test-
ing status, men in the two intervention groups and control
group A will be asked to repeat the online questionnaire.
The purpose of repeating the questionnaire will be to eval-
uate any changes in the outcomes over time. Of particular
interest is the effect on the principal outcome, knowledge,
thereby allowing an assessment of knowledge retention.
Men in control group B will also be asked at the six month
stage to complete the online questionnaire in order to
provide a control for the other three groups. All the men,
therefore, at this six month stage, will be sent a letter ask-
ing them to access and complete the online questionnaire.
This second questionnaire will have an additional ques-
tion asking men to indicate, by 'left-clicking' on corre-
sponding boxes, any types of information, newspapers/
magazines for instance, they may have used in reaching a
decision about how likely they are to have a PSA test.
v) Outcomes
Six outcomes will be measured in this study: (a) knowl-
edge of PSA and prostate cancer-related issues – this is the
main outcome of the study, on which the sample size cal-
culation is based; (b) attitudes to testing; (c) decision con-
flict; (d) anxiety; (e) intention to undergo PSA testing; (f)
uptake of the PSA test. Outcomes (a) – (e) will be gathered
from the online questionnaire. In addition to these out-
comes, based on these results, a mathematical simulation
model of the effects of Prosdex on subsequent resource use
and health outcomes will also be developed. This model
will be based on the results of the trial.
a) Knowledge of PSA and prostate cancer-related issues
Knowledge will be the principal outcome of this study.
Previous randomised controlled trials of PSA decision
aids have used knowledge as their principal outcome, and
in our systematic review of these trials we found that PSA
decision aids resulted in an improvement in knowledge of
19.5% [11]. Knowledge will be assessed using a set of
knowledge questions, used in our earlier evaluation of a
brief paper-based leaflet about PSA testing,[12] whichBMC Family Practice 2007, 8:58 http://www.biomedcentral.com/1471-2296/8/58
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showed an ability to discriminate between intervention
and control groups.
b) Attitudes to testing
This will use a 12-item scale developed and used in the
same evaluation of a brief paper-based leaflet about PSA
testing [12].
c) Decision conflict [13]
This scale measures patients' confidence or uncertainty
('conflict') about whether they feel their choice is the best
for them personally. It has acceptable validity and reliabil-
ity (internal consistency alpha coefficients range from
0.78 – 0.89; test-retest reliability coefficients exceed 0.80)
[14]. Given the nature of the decision about having a PSA
test, with a high degree of uncertainty likely to affect deci-
sion making, it is important to use this, the most widely
used outcome measure in decision aid studies [15].
d) Anxiety
This will be assessed using the short form Spielberger
questionnaire for 'state' anxiety, validated and shown to
be responsive in our earlier studies of shared decision
making and risk communication [10].
e) Intention to undergo PSA testing
This will be assessed using a single item question, with
Likert-like response scale, which has also been used in our
earlier evaluation of a brief paper-based leaflet about PSA
testing [12].
Intervention and control groups Figure 1
Intervention and control groups.
Recruited
men (600) 
Intervention
Group 1 (150)
Intervention
Group 2 (150)
Control Group 
A (150) 
Control Group 
B (150) 
Prosdex Paper version
of Prosdex text
Online
questionnaire
Online
questionnaire
Online
questionnaire
6 months: GP 
enquiry re PSA
test
6 months: GP 
enquiry re PSA
test
6 months: GP 
enquiry re PSA
test
6 months: GP 
enquiry re PSA
test
Online
questionnaire
Online
questionnaire
Online
questionnaire
Online
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f) Uptake of the PSA test
This will be assessed at six months after the intervention.
GPs who participate in the study will be asked to ascertain
the men's PSA testing status for that six month period,
from their records, and inform the research team whether
or not the test was done. The GPs will be provided with
specific forms for this purpose, to be returned to the
research team. It is possible that men may have had PSA
tests elsewhere, such as via hospital clinics, but it is likely
that these will be evenly distributed across the interven-
tion and control groups. Moreover, it may be less likely
that these decisions to be tested were patient-led. Such
'external' results, when they do occur, are increasingly
recorded in GP records.
(vi) Comparisons and analysis
Comparability of the four groups for baseline characteris-
tics of age, ethnicity, marital status and education will be
assessed. Outcomes will be compared between groups on
an 'intention to treat' basis by standard statistical tests,
including chi2 for categorical variables and t, Mann-Whit-
ney and one-way ANOVA tests for continuous and ordinal
variables. Point and interval estimates for appropriate
measures of effect size will be reported as well as p values.
A clinically significant and relevant difference in the prin-
cipal outcome, knowledge, between the two groups, will
be set at 20%. The statistical power for this study is aimed
at 90%, assuming a type 1 error rate of 5%. The sample
size will be 600 men: 150 in each of the four groups. This
figure is derived from the findings of our systematic
review of PSA decision aids where 4 RCTs (USA) were
found to result in improved knowledge of 19.5% (SD
45.1). Thus, 150 men per group will allow the detection
of a 20% absolute difference with over 90% power.
Assuming a recruitment and completion rate of 30%,
2000 men will be invited from 20 GP practices, 100 men
from each practice. For the Decisional Conflict Scale, a
comparison of any 2 groups each of 150 subjects would
detect a shift of 0.32 standard deviations, with power 80%
at the conventional 5% alpha level. The data will be col-
lected in a SQL-server database, transferred to Excel, and
then analysed using SPSS Syntax, and the results expressed
with both p values and confidence intervals.
vii) Mathematical Simulation Model
A mathematical simulation model of the effects of Prosdex
on subsequent resource use and health outcomes will also
be developed. This will use the trial outcomes, particularly
PSA uptake, to model potential diagnoses and morbidity
(drawing on existing best evidence [16]) and the resulting
resource use and workload implications at GP practice
and NHS Trust levels. For example, at GP practice level,
the age distribution in a practice will be used, together
with PSA take-up after the intervention, to estimate work-
loads and resource requirements, using appropriate sam-
pling distributions as in the investigator's previous
research.[17,18] By further sampling of GP practices
within a hospital Trust locality, estimates would be made
of the implications at Trust level for urological and other
services. The data will be obtained for local GP practices
from our network of practices who have participated in
several other research studies in recent years.
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